John Sweetenham, M.D., is a Professor in
the Department of Internal
at UT Southwestern Medical Center and the Associate Director for Clinical
Affairs at UTSW’s Harold C. Simmons Comprehensive Cancer Center. He specializes
in treating lymphomas and other hematologic malignancies.
Dr. Sweetenham earned his medical degree at Saint
Bartholomew's Hospital Medical College in London. He completed a residency at the
Royal United Hospital in Bath and received advanced training in medical
oncology through a fellowship at the University of Southampton, where he then
served as a faculty member and leader of the lymphoma and transplant programs. He
also completed a visiting fellowship in tumor immunology at Harvard Medical
School and the Dana-Farber Cancer Institute.
Prior to joining the UT Southwestern faculty in 2019, Dr.
Sweetenham was Senior Director for Clinical Affairs and Physician in Chief at
the Huntsman Cancer Institute of the University of Utah, where he led strategic
planning efforts for the clinical cancer service line and introduced innovative
cancer care delivery models.
Dr. Sweetenham is internationally recognized for his
clinical research on lymphoma and stem cell transplantation. He has authored
more than 200 original articles, chapters, and books and serves as an editor
and ad hoc reviewer for numerous scholarly journals. He has been a principal
investigator on national and international trials in lymphoma. Most recently,
he was co-leader of an international clinical trial that established a new
standard of care for patients with Hodgkin lymphoma at high risk of relapse
following stem cell transplantation. He is a former Lymphoma Committee member
of the Eastern Cooperative Oncology Group and the former Chairman of the Clinical
Trials Committee of Bloodwise (formerly Leukemia and Lymphoma Research) in the
Dr. Sweetenham is a Fellow of the American College of Physicians,
the American Society of Clinical Oncology, and the Royal College of Physicians,
UK. He is also a member of the American Society of Hematology.